Nkarta, Inc. $NKTX Position Boosted by Monaco Asset Management SAM

Monaco Asset Management SAM lifted its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 24.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,970,910 shares of the company’s stock after acquiring an additional 387,538 shares during the quarter. Nkarta makes up about 0.2% of Monaco Asset Management SAM’s portfolio, making the stock its 24th biggest holding. Monaco Asset Management SAM’s holdings in Nkarta were worth $4,080,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Savant Capital LLC acquired a new position in Nkarta in the second quarter worth approximately $36,000. SG Americas Securities LLC boosted its stake in shares of Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock worth $49,000 after acquiring an additional 6,141 shares in the last quarter. Bailard Inc. acquired a new position in shares of Nkarta in the 3rd quarter worth $61,000. CWM LLC raised its position in shares of Nkarta by 23.4% during the second quarter. CWM LLC now owns 34,758 shares of the company’s stock worth $58,000 after purchasing an additional 6,601 shares during the period. Finally, Forefront Wealth Partners LLC purchased a new stake in shares of Nkarta during the third quarter valued at $82,000. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Stock Performance

Shares of NKTX opened at $2.33 on Friday. The company has a market capitalization of $165.50 million, a PE ratio of -1.69 and a beta of 0.54. The company’s 50 day moving average price is $2.04 and its 200 day moving average price is $2.06. Nkarta, Inc. has a 52 week low of $1.31 and a 52 week high of $2.74.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Wall Street Zen raised Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a report on Monday, December 29th. Finally, Stifel Nicolaus decreased their price objective on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.25.

Insider Buying and Selling at Nkarta

In related news, CEO Paul J. Hastings sold 26,046 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total transaction of $53,915.22. Following the completion of the sale, the chief executive officer directly owned 390,023 shares in the company, valued at approximately $807,347.61. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.40% of the company’s stock.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.